Moderna Inc To Discuss SARS-CoV-2 Vaccine (mRNA-1273) Interim Phase 1 Data Transcript
Good morning, and welcome to the Moderna's Conference Call. (Operator Instructions) Please be advised that the call is being recorded. At this time, I'd like to turn the call over to Lavina Talukdar, Head of Investor Relations at Moderna.
Thank you, operator. Good morning, everyone, and welcome to Moderna's Conference Call to discuss the interim Phase I data for mRNA-1273, our vaccine against the novel coronavirus. You can access the press release issued this morning as well as the slides that we'll be reviewing by going to the Investors section of our website.
Speaking on today's call are Stéphane Bancel, our Chief Executive Officer; Tal Zaks, our Chief Medical Officer; Stephen Hoge, our President; and Lorence Kim, our Chief Financial Officer.
Before we begin, please note that this conference call will include forward-looking statements. Please see Slide 2 of the accompanying presentation and our SEC filings for important risk factors that could cause our actual performance and results to differ
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |